上肢骨折老年人中评估和管理肌少症与衰弱的可行性与可接受性
本研究在英国一个城市的骨折门诊招募100名65岁以上上肢骨折患者,评估肌少症和衰弱的多种工具的可行性与可接受性。肌少症检出率4-39%、衰弱9-25%因工具而异,SARC-F和PRISMA-7敏感性最佳,转诊CGA的参与者中80%接受了干预。
要点
- SARC-F和PRISMA-7推荐用于骨折门诊筛查肌少症和衰弱。
- 多数评估工具快速、数据完整且患者和工作人员可接受。
- 转诊CGA的参与者中80%接受干预,人均三项干预。
核心结论
- SARC-F和PRISMA-7推荐用于骨折门诊筛查肌少症和衰弱。
研究设计与样本
- 在英国一个城市骨折门诊招募100名65岁以上上肢骨折患者,评估多种肌少症和衰弱工具的可行性与可接受性,并对13名患者和9名工作人员进行访谈。
主要发现
- 肌少症检出率4-39%取决于工具,衰弱检出率9-25%。
- 所有工具下两种状况在男性中均比女性更常见。
- SARC-F和PRISMA-7敏感性分别为100%和93%,特异性分别为96%和87%。
- 转诊CGA的参与者中80%接受干预,人均三项干预(如药物调整和检查)。
关键数值与推荐
- 肌少症评估采用步速、握力、骨骼肌质量指数SMI、SARC-F问卷及EWGSOP I和II标准。
- 衰弱评估采用Fried衰弱表型(FFP)、FRAIL量表、PRISMA-7、电子衰弱指数(e-FI)、临床衰弱评分(CFS)和骨质疏松性骨折研究工具。
- 各工具敏感性和特异性以EWGSOP II标准(肌少症)和FFP(衰弱)为参照计算。
临床怎么用
- 在骨折门诊使用SARC-F筛查肌少症、PRISMA-7筛查衰弱,识别后转诊CGA。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: sarcopenia and frailty are associated with increased risk of falls and fractures. This study evaluated the feasibility of assessing sarcopenia and frailty among older people attending fracture clinics. METHODS: patients aged 65+ years with an arm fracture attending fracture clinics in one UK city were recruited. Sarcopenia was assessed using gait speed, grip strength, skeletal muscle mass index SMI, SARC-F questionnaire and the European Working Group on Sarcopenia in Older People (EWGSOP) I and II criteria. Frailty was assessed using Fried Frailty Phenotype (FFP), FRAIL scale, PRISMA-7, electronic Frailty Index (e-FI), Clinical Frailty Score (CFS) and Study of Osteoporotic Fracture. The sensitivity and specificity of each tool was calculated against the EWGSOP II criteria (sarcopenia) and FFP (frailty). Patients identified to have either condition were referred for Comprehensive Geriatric Assessment (CGA). Interviews with 13 patients and nine staff explored the acceptability of this process. RESULTS: hundred patients (Mean age 75 years) were recruited. Most sarcopenia and frailty assessments were quick with complete data collection and were acceptable to patients and staff. Sarcopenia was identified among 4-39% participants depending on the tool and frailty among 9-25%. Both conditions were more common among men than women with all tools. The SARC-F and PRISMA-7 had the best sensitivity (100 and 93%, respectively) and specificity (96 and 87%). CGA among 80% of referred participants led to three interventions per participant (e.g. medication changes and investigations). CONCLUSION: SARC-F and PRISMA-7 are recommended for use in fracture clinics to screen for sarcopenia and frailty.
引用
- Ibrahim K, Mullee MA, Cox N, et al. The feasibility and acceptability of assessing and managing sarcopenia and frailty among older people with upper limb fracture. Age Ageing. 2022. PMID: 34977920. doi:10.1093/ageing/afab252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。